Cl[C:2]1[N:7]=[CH:6][C:5]([CH2:8][N+:9]2[C:14]([O-:15])=[C:13]([C:16]3[CH:21]=[CH:20][CH:19]=[C:18]([C:22]#[N:23])[CH:17]=3)[C:12](=[O:24])[N:11]3[CH:25]=[CH:26][CH:27]=[CH:28][C:10]=23)=[CH:4][CH:3]=1.[ClH:29].[OH:30][NH3+:31].CC(C)([O-])C.[K+]>CS(C)=O.[Cl-].[Na+].O>[Cl:29][C:2]1[N:7]=[CH:6][C:5]([CH2:8][N+:9]2[C:14]([O-:15])=[C:13]([C:16]3[CH:21]=[CH:20][CH:19]=[C:18]([C:22](=[NH:23])[NH:31][OH:30])[CH:17]=3)[C:12](=[O:24])[N:11]3[CH:25]=[CH:26][CH:27]=[CH:28][C:10]=23)=[CH:4][CH:3]=115 mg (0.04 mmol) of 1-[(6-chloro-3-pyridyl)methyl]-3-(3-cyanophenyl)-4-oxo-pyrido[1,2-a]pyrimidin-1-ium-2-olate (product of step 1) were dissolved in 2 ml DMSO. 7 mg (0.1 mmol) hydroxylammonium hydrochloride and 11 mg (0.1 mmol) potassium t-butoxide were added and the mixture was stirred at 50° C. for 48 hours. The mixture was taken up with 10 ml of brine and extracted with ethyl acetate. The organic phases were dried with magnesium chloride and the solvent was removed under reduced pressure. The desired product was sufficiently pure without further purification (5 mg). HPLC-MS: 1.75 min, M=422.5